Mixed
Co-administration of the GLP-1 receptor agonist liraglutide and nicotine synergistically lowers body weight in obese mice by simultaneously reducing food intake and increasing energy expenditure.
In obese mice, combining a GLP-1 drug (liraglutide) with nicotine resulted in greater weight loss than either drug alone. This happened because the combination reduced hunger more effectively and increased the body's energy expenditure. This suggests that for humans, smokers might experience enhanced weight loss from GLP-1 medications, or that specific nicotine-targeting strategies could boost GLP-1 efficacy.
The co-administration treatment synergistically lowered body weight over 16 days relative to the individual monotheries... the weight loss following treatment with the combination of liraglutide and nicotine is, at least partially, driven by potentiated anorexia... suggesting a contribution from increased energy expenditure to the weight loss
Why this rating
High-quality preclinical evidence using multiple methodologies (body composition, pair-feeding, electrophysiology, transcriptomics) in a controlled animal model, though not human.
Source
GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity
Sarah Falk et al. · Cell Reports · 2023
DOI 10.1016/j.celrep.2023.112466
More from this paper
- GLP-1 receptor agonism (liraglutide) sensitizes hypothalamic POMC neurons and ventral tegmental area (VTA) dopaminergic neurons to nicotine, increasing their excitability and contributing to weight loss.Good
- Liraglutide attenuates nicotine-induced dopamine release in the nucleus accumbens (NAc), potentially reducing the addictive properties of nicotine while maintaining weight loss benefits.Moderate
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →